Waiting to Exhale with Afrezza
Insulin Nation
APRIL 4, 2014
'If you want to experience the emotional rollercoaster that comes with rooting for Afrezza, an inhalable insulin product, look no further than the stock price of Mannkind, Afrezza’s creator. Leading up to a FDA panel review of Afrezza on April 1st, Mannkind shares tanked badly. But once FDA advisors came back with a surprise 13-1 vote in favor of Afrezza for treating T1, the price of Mannkind’s shares shot up 75% in just 4 days.
Let's personalize your content